Non small cell lung cancer patients with ECOG PS2: Unsolved questions and lessons from clinical trials

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  Gebbia, Vittorio ^a,d   Galetta, D ^b   De Marinis, F ^c  

^a LA MADDALENA CANCER CENTER   (Italy)

^b Istituto dei Tumori   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d NONE   (Italy)

Author keywords

Best supportive care; Chemotherapy; Lung cancer; Performance status 2

Indexed keywords

ALKALINE PHOSPHATASE; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEFITINIB; GEMCITABINE; HEMOGLOBIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; PACLITAXEL POLIGLUTAMEX; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VINDESINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; CONSENSUS; DEHYDRATION; DRUG DOSE REGIMEN; DRUG EXPOSURE; FATIGUE; HUMAN; LIVER METASTASIS; LUNG NON SMALL CELL CANCER; MEDICAL DECISION MAKING; META ANALYSIS; METASTASIS POTENTIAL; MYALGIA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; POLYPHARMACY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; SKIN METASTASIS; SURVIVAL RATE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT PLANNING; VOMITING;

EID: 30644460000     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi921     Document Type: Article

References (70)

1. Bunn PA. Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why? J Clin Oncol 2002; 20 (Suppl): 23s-33s.
2. Lilenbaum R. Management of Advanced Non-Small-Cell Lung Cancer in Patients with a Performance Status of 2. Clin Lung Cancer 2004; 5: 209-213.
3. Stanley KE. Prognostic factor for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65: 25-32.
4. Jiroutek M, Johnson D, Blum R et al. Prognostic factors in advanced non-small-cell lung cancer: Analysis of Eastern Cooperative Oncology Group trials from 1981-1992. Proc Am Soc Clin Oncol 1998; 17: 461.
5. Albain KS, Crowley JJ, LeBlanc M et al. Survival determinants in extensive-stage non-small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991; 9: 1618-1626.
6. Paesmans M, Sculier JP, Libert P et al. Prognostic factors for survival in advanced non small-cell lung cancer: Univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995; 13: 1221-1230.
7. Hoang T, Xu R, Schiller JH et al. Clinical model to predict survival in chemo-naive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol 2005; 23: 175-183.
8. Hickish TF, Smith IE, O'Brien ME et al. Clinical benefit from palliative chemotherapy in non-small cell lung cancer extends to the elderly and those with poor prognostic factors. Br J Cancer 1998; 78: 28-33.
9. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with un-resectable non-small-cell lung cancer. Ann Oncol 2001; 12: 1671-1675.
10. Buccheri G, Ferrigno D, Tamburini M. Karnofsky and ECOG performance status scoring in lung cancer: A prospective, longitudinal study of 536 patients from a single institution. Eur J Cancer 1996; 32A: 1135-1141.
11. Kelly K. Challenges in defining and identifying patients with non-small cell lung cancer and poor performance status. Semin Oncol 2004; 31 (Suppl. 11): 3-7.
12. Gridelli C, Ardizzoni A, Le Chevalier T et al. Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of a European Experts Panel. Ann Oncol 2004; 15: 419-426.
13. Langer C, Lilienbaum R. Patients with non-small cell lung cancer and poor performance status: A significant population with limited data. Semin Oncol 2004; 31 (Suppl. 11): 1-2.
14. Govindan DH, Garfield DH: Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 2004; 31 (Suppl. 11): 27-31.
15. Karnofsky D, Abelman W, Craver L. The use of nitrogen mustard in the palliative treatment of carcinoma with particular reference to bronchogenic carcinoma. Cancer 1948; 1: 634-656.
16. Zubrod C, Scheniderman M, Frei E. Appraisal of methods for the study of chemotherapy in man: Comparative therapeutic trial of nitrogen mustard and triethylenethiophosphoramide. J Chron Dis 1960; 11: 7-33.
17. Roila F, Luppatelli M, Sassi M et al. Intra and inter-observer variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales. Ann Oncol 1991; 2: 437-439.
18. Verger E, Salamero M, Conill C. Can Karnofsky performance status be transformed to the Eastern Oncology Group scoring scale and vice versa ? Eur J Cancer 1992; 28A: 1328-1330.
19. Taylor AE, Olver IN, Sivanthan T et al. Observer error in grading performance status in cancer patients. Support Care Cancer 1999; 7: 332-335.
20. Ando M, Ando Y, Hasegawa Y. Prognostic value of performance status assessed by patients themselves, nurses and oncologists in advanced non-small cell lung cancer. Br J Cancer 2001; 85: 1634-1639.
21. Cullen MH, Billingham LJ, Woodroffe CM et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: Effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-3194.
22. Billingham LJ, Cullen MH. The benefits of chemotherapy in patient subgroups with unresectable non-small-cell lung cancer. Ann Oncol 2001; 12: 1671-1675.
23. Group NSCLCCO. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.
24. Bunn PA, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: A review of the literature and future directions. Clin Cancer Res 1998; 4: 1087-1100.
25. The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72.
26. Ranson M, Davidson N, Nicolson M et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-1080.
27. Roszkowski K, Pluzanska A, Krzakowski M et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-näive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27: 145-157.
28. Gridelli C, Hainsworth J. Meeting the chemotherapy needs of elderly and poor performance status patients with NSCLC. Lung Cancer 2002; 38: S37-S41.
29. Anderson H, Hopwood P, Stephens RJ et al. Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small cell lung cancer: A randomized trial with quality of life as the primary outcome. Br J Cancer 2000; 83: 447-453.
30. Cella D. Quality of life consideration in patients with advanced lung cancer. Semin Oncol 2004; 31 (Suppl 11): 16-20.
31. Lilenbaum R, Langerberg P, Dickersin K. Single agent versus combination chemotherapy in patients with advanced non small cell lung carcinoma: A meta-analysis of response, toxicity and survival. Cancer 1988; 82: 116-126.
32. Le Chevalier T, Brisgand D, Douillard JY et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: Results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360-367.
33. Le Chevalier T, Brisgand D, Soria JC et al. Long term analysis of survival in the European randomized trial comparing vinorelbine/ cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer. Oncologist 2001; 6 (Suppl. 1): 8-11.
34. Lilenbaum R, Herndon J, List M et al. Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: A CALGB randomised trial of efficacy, quality of life and cost-effectiveness. Proc Am Soc Clin Oncol 2002; 21: 1a.
35. Gridelli C, Perrone F, Gallo C et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
36. Kosmidis PA, Dimopoulos MA, Syrigos C et al. Gemcitabine (G) versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer (NSCLC) and PS2: A prospective randomised phase II trial of the Hellenic Co-Operative Oncology Group. J Clin Oncol 2004; Proceedings of the 40th ASCO 2004; 23: 23 (Abstr 7058).
37. Schiller JH, Harrington D, Belani CP et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346: 92-98.
38. Sweeney CJ, Zhu J, Sandler AB et al. Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group E1594: A phase II trial in patients with metastatic non small cell lung carcinoma. Cancer 2001; 15: 2639-2647.
39. Alberola V, Camps C, Provencio M et al. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: A Spanish Lung Cancer Group phase III randomized trial. J Clin Oncol 2003; 21: 3207-3213.
40. Crinò L, Novello S, Migliorino MR et al. A phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer (NSCLC): Impact of PS = 2 versus 0 or 1 and age >70 versus <70 on chemotherapy outcome. Proc Am Soc Clin Oncol 2002; 21: 315a (Abstr 1258).
41. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. Italian Lung Cancer Project. J Clin Oncol 2002; 20: 4285-4291.
42. Gebbia V, Galetta D, Maiello E et al. Treatment of stage III-IV non-small cell lung carcinoma with vinorelbine in combination with ifosfamide plus mesna: A study of the Southern Italy Oncology Group (GOIM). Am J Clin Oncol 1996; 19: 278-280.
43. Colucci G, Gebbia V, Galetta D et al. Cisplatin and vinorelbine followed by ifosfamide plus epirubicin versus the opposite sequence in advanced un-resectable stage III and metastatic stage IV non-small-cell lung cancer: A prospective randomised study of the Southern Italy Oncology Group (GOIM). Br J Cancer 1997; 76: 1509-1517.
44. Gebbia V, Caruso M, Valenza R et al. Vinorelbine plus cisplatinum for the treatment of stage IIIB and IV non small cell lung cancer. Anticancer Res 1994; 14: 1247-1250.
45. Gebbia V, Caruso M, Galetta D. Weekly vinorelbine plus cisplatin versus day 1+8 vinorelbine with cisplatin in advanced non small cell lung cancer: End results of a phase II trial. IASLC 2005.
46. Gebbia V, Galetta D, Riccardi F et al. Vinorelbine plus cisplatin versus cisplatin plus vindesine and mitomycin C in stage IIIB-IV non-small cell lung carcinoma: A prospective randomised study. Lung Cancer 2002; 37: 179-197.
47. Gebbia V, Galetta D, Caruso M et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin vesus ifosfamide + Gemcitabine followed by ifosfamide and Gemcitabine in stage IIIB-IV non small cell lung cancer: a prospective trial of the Gruppo Oncologico Italia Meridonale. Lung Cancer 2003; 39: 179-189.
48. Kosmidis P, Mylonakis N, Nicolaoides C et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non small cell lung cancer. J Clin Oncol 2002; 20: 3578-3585.
49. Tester WJ, Stephenson P, Langer CJ, et al. ECOG 1519: Randomised phase II study of paclitaxel/carboplatin or gemcitabine/cisplatin in performance status (PS) 2 patients with advanced non-small lung cancer (NSCLC). Proceedings of the 40th ASCO 2004; 23: 627 (abstract 7055).
50. Langer CJ. Dilemmas in Management: The controversial role of chemotherapy in PS2 advanced NSCLC and the potential role of CT-2103 (Xyotax™). The Oncologist 2004; 9: 398-405.
51. Galetta D, Gebbia V, Giotta F et al. Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: A phase II study of the Gruppo Oncologico Italia Meridionale. Lung Cancer 2002; 38: 79-84.
52. Weissman CH, Sandbach JF, Brooker RJ et al. A phase II study of weekly docetaxel and carboplatin in stage IIIB (with effusion) or stage IV non-small cell lung cancer patients age <65 years and performance status 2. Proc ASCO 2004; (abstr. 7276).
53. Latreille J, Hirsh V, Kreisman H et al. Sequential therapy with vinorelbine followed by Gemcitabine in patients with metastatic non-small cell lung cancer (NSCLC), performance status (PS) 2 or elderly with co-morbidities: A multi-centre phase II trial. Proceedings of the 40th ASCO 2004; 23: 7303 (abstr. 7119).
54. Spiridonidis H, Tao M, Laufman L et al. Symptomatic response to a non-platinum doublet in performance status 2 (PS2) patients (pts) with non-small cell lung cancer (NSCLC). Proceedings of the 40th ASCO 2004; 23: 7303 (abstract 7303).
55. Lilenbaum R, Rubin M, Samuel J et al. A phase II randomized trial of docetaxel weekly or every 3 weeks in elderly and/or poor performance status (PS) patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 2004; 23: 267 (abstract 7057).
56. Hesketh PJ, Chansky K, Lau DH et al. Sequential vinorelbine (V) and docetaxel (D) in advanced non-small cell lung cancer (NSCLC) patients age >70, or with performance status (PS) 2: A SWOG phase II trial (S0027). Proceedings of the ASCO 2004; 23: 267 (abstract 7056).
57. Dickson NR, Hainsworth JD, Spigel DR et al. Single agent gefinitib in poor performance status patients with previously untreated non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial. Proceedings of the 40th ASCO 2004 (abstract 7086).
58. Langer C, Lilienbaum R. Role of chemotherapy in patients with poor performance status and advanced non-small cell lung cancer. Sem Oncol 2004; 31 (Suppl. 11): 8-15.
59. Kris MG, Natale RB, Herbs RE et al. Efficacy of gefinitib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. J Am Med Assoc 2003; 291: 2149-2158.
60. Blackhall FH, Bhosle J, Thatcher N. Chemotherapy for advanced non-small cell lung cancer patients with performance status 2. Curr Opin Oncol 2005; 17: 135-139.
61. Pfister GD, Johnston DH, Azzoli CG et al. American Society of Clinical Oncology treatment of unresectable non-small cell lung cancer guidelines: Update 2003. J Clin Oncol 2003; 22: 330-353.
62. De Groot V, Beckerman H, Lankhorst GJ et al. How to measure comorbidity: a critical review of available methods. J Clin Epidemiol 2003; 56: 221-229.
63. Govindan R, Garfield DH. Treatment approaches in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 2004; 31 (Suppl. 11): 27-31.
64. Deppermann KM. Influence of age and comorbidities on the chemotherapeutic management of lung cancer. Lung Cancer 2001; 33 (Suppl. 1): S115-S120.
65. Firat S, Byhardt RW, Gore E. Co-morbidity and Karnofsky performance score are independent prognostic factors in stage III non-small cell lung cancer: An institutional analysis of patients treated on four RTOG studies. Int J Radiat Oncol Biol Phys 2002; 54: 357-364.
66. Repetto L, Fratino L, Audisio RA et al. Comprehensive geriatric assessment adds information to eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 2003; 15: 494-502.
67. Dalzell MA, Kreisman H, Small D et al. Is performance status related to functional capacity in patients with non small lung cancer (NSCLC)? J Clin Oncol 2004; 22 (Suppl.): 7224.
68. Eton DT, Fairclough DL, Cella D et al. Early changes in patients reported health during cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003; 21: 1536-1543.
69. Langer C, Barsevick A, Bruner D et al. Correlation of quality of life (QOL) with survival, treatment response and anemia in patients advanced non-small cell lung cancer (NSCLC) treated with carboplatin and paclitaxel. Lung Cancer 1997; 18: 23 (abstract).
70. Stinchcombe TE, Socinski MA. Drug development in patients with advanced non-small cell lung cancer and poor performance status. Semin Oncol 2004; 31 (Suppl. 11): 21-26.